Last quarter (Q ), Cannapharmarx's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Cannapharmarx's net income was $-564.37K. See Cannapharmarx’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 5.48M	$ 5.21M	$ 2.62M	$ 4.64M	$ 2.98M	$ 532.77K
Operating Income	$ -5.48M	$ -5.21M	$ -2.62M	$ -4.64M	$ -2.98M	$ -532.77K
Net Non Operating Interest Income Expense	$ -2.02M	$ -2.29M	$ 1.51M	$ 2.29M	$ -4.47M	$ -2.14M
Other Income Expense	$ -4.98K	$ 1.03M	$ -4.71M	$ -12.96M	$ -13.00M	$ -421.48K
Pretax Income	$ -7.50M	$ -8.53M	$ -8.83M	$ -19.89M	$ -20.45M	$ -3.09M
Tax Provision	-	-	-	-	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -7.50M	$ -8.53M	$ -8.83M	$ -19.89M	$ -20.45M	$ -3.09M
Basic EPS	$ -0.02	$ -0.04	$ -0.12	$ -0.49	$ -0.66	$ -0.17
Diluted EPS	$ -0.02	$ -0.04	$ -0.12	$ -0.49	$ -0.66	$ -0.17
Basic Average Shares	$ 1.14B	$ 211.04M	$ 74.69M	$ 40.70M	$ 31.17M	$ 17.96M
Diluted Average Shares	$ 1.14B	$ 211.04M	$ 74.69M	$ 40.70M	$ 31.17M	$ 17.96M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	$ 54.45K	$ 9.00K
Total Expenses	$ 5.48M	$ 5.21M	$ -2.62M	$ -4.64M	$ 2.98M	$ 532.77K
Net Income From Continuing And Discontinued Operation	$ -7.50M	$ -8.53M	$ -8.83M	$ -19.89M	$ -20.45M	$ -3.09M
Normalized Income	$ -5.51M	$ -6.27M	$ -5.29M	$ -5.34M	$ -7.45M	$ -2.67M
Interest Expense	-	-	-	-	$ 4.47M	$ 2.14M
EBIT	$ -5.48M	$ -6.24M	$ -7.33M	$ -17.60M	$ -15.98M	$ -954.25K
EBITDA	$ -5.09M	$ -5.47M	$ -7.32M	$ -17.47M	$ -15.85M	$ -954.25K

Currency in USD

Cannapharmarx Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing